search
Back to results

Saracatinib Trial TO Prevent FOP (STOPFOP)

Primary Purpose

Fibrodysplasia Ossificans Progressiva

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
AZD0530 Difumarate
Matching placebo
Sponsored by
Amsterdam UMC, location VUmc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fibrodysplasia Ossificans Progressiva focused on measuring Fibrodysplasia Ossificans Progressiva, AZD0530, Saracatinib, Stone man syndrome, FOP

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female aged 18-65 with a clinical diagnosis of FOP at screening, including congenital malformation of the great toes and a history of spontaneous or injury-induced heterotopic ossification (HO), and have a confirmed classic FOP phenotype by the documentation of an ACVR1R206H/+ genomic sequence.

    1. Female participants who are women of child-bearing potential will be required to use a highly effective method of contraception as defined in section 5.4, in combination with a condom or diaphragm or cervical/vault caps with spermicidal foam/gel/film/suppository), from the time of enrolment until 4 weeks after final dose of study drug, unless practicing true sexual abstinence as defined in section 5.4.
    2. Male participants will be required to avoid procreative sexual intercourse with women of child-bearing potential from time of enrollment until 4 weeks after final dose of study drug through use of highly effective contraceptive methods. Male participants with a pregnant female partner will be required to use a condom for the duration of the study and for 4 weeks final dose of study drug. Male study participants will not be permitted to donate sperm for from the time of enrolment and until 4 weeks after final dose of study drug.
  2. Participants will have to be able to understand and complete study and willing to sign informed consent (IC). They have to be able to attend and comply with the study visits and related activities, adhere to all study-related restrictions, and able to undergo procedures such as PET and CT imaging.

Exclusion Criteria:

  1. Not willing to strictly adhere to the reproductive restrictions as defined in section 5.4
  2. Women who are pregnant or breast-feeding (from the time 3 months prior to 4 weeks after completion of participation in the study)
  3. The presence of significant concomitant illness or history of significant illness such as cardiac, respiratory, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, lymphatic disease, or infectious disease, that might confound the results of the study or pose additional risk to the patient;
  4. Evidence of active bleeding (including hematuria or hematochezia,) acute or chronic gastrointestinal illness, inflammatory bowel disease, or mucositis
  5. Malignant disease / cancer requiring treatment in the past 3 years (except some primary non melanoma skin cancer);
  6. Severely impaired renal function defined as estimated glomerular filtration rate <30 mL/min/1.73 m2 calculated by the Modification of Diet in Renal Disease equation;
  7. Showing uncontrolled diabetes mellitus with an HbA1C > 9%;
  8. Significant viral illness or active infections at screening or randomisation; Subjects should not have subacute or acute fevers of >101 degrees F at time of screening or randomisation
  9. Evidence of prolonged QT interval at screening or randomization (defined as QTc of >450 ms) .or known congenital long-QT syndrome.
  10. Neutropenia defined as an absolute neutrophil count of <1,500/µl,
  11. Thrombocytopenia defined as platelet count <100 × 103/µl,
  12. Current blood clotting or bleeding disorder, or significantly abnormal INR-prothrombin time or partial thromboplastin time at screening, or clinically significant abnormalities in other screening laboratories, including significant abnormalities in vitamin B12 or thyroid function tests would be cause for exclusion.-
  13. Abnormal liver function test results defined as aspartate aminotransferase (AST) >2.0 x upper limit of normal (ULN); alanine aminotransferase (ALT) >2.0 x ULN; and / or total bilirubin >1.5 x ULN;
  14. Known allergy or intolerance to AZD0530 or any excipients used in the investigational medicinal products.
  15. Simultaneous participation in another interventional clinical study or a non-interventional study with imaging measures or invasive procedures (eg. collection of blood or tissue samples); Participation in the FOP Connection Registry (www.fopconnection.org) or other studies in which patients completed study questionnaires are possible.
  16. Treatment with another investigational or drug that might interfere with HO formation and the interpretation of the study drug in the last 90 days
  17. Current use or history of regular alcohol consumption exceeding 14 units/week (6 glasses of 13.0% wine (175ml), 6 pints of 4.0% lager or ale (568ml), 5 pints of 4.5% cider (568 ml) or 14 glasses of 10.0% spirits (25ml)) within 6 months of screening.
  18. Currently active metabolic bone disease, other than FOP.

Sites / Locations

  • Klinikum Garmish-PartenkirchenRecruiting
  • Amsterdam University Medical CenterRecruiting
  • Royal National Orthopaedic Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

AZD0530

Placebo/AZD0530

Arm Description

Outcomes

Primary Outcome Measures

The objective change between the two arms measured in heterotopic bone volume measured by low-dose whole body CT over the initial 6 month RCT

Secondary Outcome Measures

Safety and tolerability assessments are the incidence and severity of adverse events (AE) during the RCT at the end of week 28.
The change in heterotopic bone volume measured by low-dose whole body CT over six-months treatment during open-label extension of AZD0530 compared to the previous placebo arm of the RCT
The change in heterotopic bone volume measured by low-dose whole body CT over twelve-months treatment during open-label extension of AZD0530 compared to the historical data of Clementia (NCT02322255)
Change in the volume of individual HO lesions
measured by low-dose whole body CT over the initial 6 month RCT and the change over twelve-months therapy during open-label extension of AZD0530 compared to the historical data of Clementia and compared to the 6 months placebo-arm.
Change in number of HO lesions measured by CT over the initial 6 month RCT and in addition the change over twelve-months during open-label extension of AZD0530 compared to the historical data of Clementia and compared to the 6 months placebo-arm.
In patients with at least 1 active lesion at baseline: Change (and Area Under the Curve (AUC) analysis) of lesion activity
by 18F-NaF PET over the initial 6 month RCT and over months 6-12 compared to the 6 months RCT of the placebo arm, including change from baseline in 18F-NaF Standard Uptake Volume (SUVmean or peak) of individual active HO site
In patients with at least 1 active lesion at baseline: Change in number of active lesion on 18F-NaF PET from baseline to 6 and 12months
Change and percent change from baseline in biomarkers of bone formation levels in serum over time.
Including Total Procollagen Type 1 N-Terminal Propeptide (P1NP), Alkaline Phosphatase (AP) fasting cross-linked C-terminal telopeptide of type I colla-gen (βCTX). Selected genetic markers for FOP activity
Joint function assessment by physician at baseline and week 3, month 3,6,9,12,and18 by the cumulative analog joint involvement scale (CAJIS) and the quantitative detailed multi-joint assessment at baseline and month 6, 12 and 18
Patient-reported global health status the 36-item Short Form Health Survey (SF-36) at baseline and week 3, month 3,6,9,12,and 18
FOP disease activity assessed by movement disabilities and quality of life using FOP Independent Activity of Daily Living (FOP I-ADL)
Number of reported flare-ups by the patient
Pharmacokinetic measurements: blood for determination of plasma concentrations of AZD0530 (pre-dose)on the day of the study visits at 6, 12 and 18months

Full Information

First Posted
March 11, 2020
Last Updated
July 21, 2022
Sponsor
Amsterdam UMC, location VUmc
Collaborators
Royal National Orthopaedic Hospital NHS Trust, Klinikum Garmisch-Patenkirchen, University of Oxford, Brigham and Women's Hospital, AstraZeneca, Innovative Medicines Initiative
search

1. Study Identification

Unique Protocol Identification Number
NCT04307953
Brief Title
Saracatinib Trial TO Prevent FOP
Acronym
STOPFOP
Official Title
Saracatinib Trial TO Prevent FOP
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 5, 2020 (Actual)
Primary Completion Date
August 1, 2024 (Anticipated)
Study Completion Date
August 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Amsterdam UMC, location VUmc
Collaborators
Royal National Orthopaedic Hospital NHS Trust, Klinikum Garmisch-Patenkirchen, University of Oxford, Brigham and Women's Hospital, AstraZeneca, Innovative Medicines Initiative

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a phase 2 study, designed as a European multicentre 6-month double blind random-ized controlled trial (RCT) of AZD0530 versus matched placebo, followed by a 12 month trial comparing open-label extended AZD0530 treatment with historical control data. Study population: Male and female adult patients aged 18 years and older with a diagnosis of FOP who meet the inclusion (active disease) and exclusion criteria will be eligible for participation in this study. The total number of enrolled patients will be 20. Intervention: Patients will be randomized to receive either AZD0530 100mg once daily or matched placebo, taken orally for the first 6 months, immediately followed by an open-label extension in which all patients will receive AZD0530 100mg once daily oral dose for a further 12 months. Endpoints: Endpoints include objective change in heterotopic bone volume measured by low-dose whole-body computer tomography (CT) , [18F] NaF Positron Emission Tomography (PET) activity and patient reported outcome measures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibrodysplasia Ossificans Progressiva
Keywords
Fibrodysplasia Ossificans Progressiva, AZD0530, Saracatinib, Stone man syndrome, FOP

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
6-month double blind randomized controlled trial of AZD0530 versus placebo, followed by a 12 month open label extension phase
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AZD0530
Arm Type
Experimental
Arm Title
Placebo/AZD0530
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
AZD0530 Difumarate
Other Intervention Name(s)
Saracatinib
Intervention Description
AZD0530 for the duration of the trial
Intervention Type
Drug
Intervention Name(s)
Matching placebo
Intervention Description
Matching placebo during 6 month RCT, AZD0530 thereafter
Primary Outcome Measure Information:
Title
The objective change between the two arms measured in heterotopic bone volume measured by low-dose whole body CT over the initial 6 month RCT
Time Frame
Baseline, month 6
Secondary Outcome Measure Information:
Title
Safety and tolerability assessments are the incidence and severity of adverse events (AE) during the RCT at the end of week 28.
Time Frame
Baseline, month 6 (+overall duration study)
Title
The change in heterotopic bone volume measured by low-dose whole body CT over six-months treatment during open-label extension of AZD0530 compared to the previous placebo arm of the RCT
Time Frame
Baseline, month 6, month 12
Title
The change in heterotopic bone volume measured by low-dose whole body CT over twelve-months treatment during open-label extension of AZD0530 compared to the historical data of Clementia (NCT02322255)
Time Frame
Baseline, month 6, month 12, month 18
Title
Change in the volume of individual HO lesions
Description
measured by low-dose whole body CT over the initial 6 month RCT and the change over twelve-months therapy during open-label extension of AZD0530 compared to the historical data of Clementia and compared to the 6 months placebo-arm.
Time Frame
Baseline, month 6, month 12, month 18
Title
Change in number of HO lesions measured by CT over the initial 6 month RCT and in addition the change over twelve-months during open-label extension of AZD0530 compared to the historical data of Clementia and compared to the 6 months placebo-arm.
Time Frame
Baseline, month 6, month 12, month 18
Title
In patients with at least 1 active lesion at baseline: Change (and Area Under the Curve (AUC) analysis) of lesion activity
Description
by 18F-NaF PET over the initial 6 month RCT and over months 6-12 compared to the 6 months RCT of the placebo arm, including change from baseline in 18F-NaF Standard Uptake Volume (SUVmean or peak) of individual active HO site
Time Frame
Baseline, month 6, month 12
Title
In patients with at least 1 active lesion at baseline: Change in number of active lesion on 18F-NaF PET from baseline to 6 and 12months
Time Frame
Baseline, month 6, month 12
Title
Change and percent change from baseline in biomarkers of bone formation levels in serum over time.
Description
Including Total Procollagen Type 1 N-Terminal Propeptide (P1NP), Alkaline Phosphatase (AP) fasting cross-linked C-terminal telopeptide of type I colla-gen (βCTX). Selected genetic markers for FOP activity
Time Frame
Baseline, week 3 through month 18
Title
Joint function assessment by physician at baseline and week 3, month 3,6,9,12,and18 by the cumulative analog joint involvement scale (CAJIS) and the quantitative detailed multi-joint assessment at baseline and month 6, 12 and 18
Time Frame
baseline, week 3, month 3,6,9,12,and 18
Title
Patient-reported global health status the 36-item Short Form Health Survey (SF-36) at baseline and week 3, month 3,6,9,12,and 18
Time Frame
baseline, week 3, month 3,6,9,12,and 18
Title
FOP disease activity assessed by movement disabilities and quality of life using FOP Independent Activity of Daily Living (FOP I-ADL)
Time Frame
baseline, week 3, month 3,6,9,12,and 18
Title
Number of reported flare-ups by the patient
Time Frame
Each day (day 0-month18)
Title
Pharmacokinetic measurements: blood for determination of plasma concentrations of AZD0530 (pre-dose)on the day of the study visits at 6, 12 and 18months
Time Frame
6,12 and 18months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female aged 18-65 with a clinical diagnosis of FOP at screening, including congenital malformation of the great toes and a history of spontaneous or injury-induced heterotopic ossification (HO), and have a confirmed classic FOP phenotype by the documentation of an ACVR1R206H/+ genomic sequence. Female participants who are women of child-bearing potential will be required to use a highly effective method of contraception as defined in section 5.4, in combination with a condom or diaphragm or cervical/vault caps with spermicidal foam/gel/film/suppository), from the time of enrolment until 4 weeks after final dose of study drug, unless practicing true sexual abstinence as defined in section 5.4. Male participants will be required to avoid procreative sexual intercourse with women of child-bearing potential from time of enrollment until 4 weeks after final dose of study drug through use of highly effective contraceptive methods. Male participants with a pregnant female partner will be required to use a condom for the duration of the study and for 4 weeks final dose of study drug. Male study participants will not be permitted to donate sperm for from the time of enrolment and until 4 weeks after final dose of study drug. Participants will have to be able to understand and complete study and willing to sign informed consent (IC). They have to be able to attend and comply with the study visits and related activities, adhere to all study-related restrictions, and able to undergo procedures such as PET and CT imaging. Exclusion Criteria: Not willing to strictly adhere to the reproductive restrictions as defined in section 5.4 Women who are pregnant or breast-feeding (from the time 3 months prior to 4 weeks after completion of participation in the study) The presence of significant concomitant illness or history of significant illness such as cardiac, respiratory, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, lymphatic disease, or infectious disease, that might confound the results of the study or pose additional risk to the patient; Evidence of active bleeding (including hematuria or hematochezia,) acute or chronic gastrointestinal illness, inflammatory bowel disease, or mucositis Malignant disease / cancer requiring treatment in the past 3 years (except some primary non melanoma skin cancer); Severely impaired renal function defined as estimated glomerular filtration rate <30 mL/min/1.73 m2 calculated by the Modification of Diet in Renal Disease equation; Showing uncontrolled diabetes mellitus with an HbA1C > 9%; Significant viral illness or active infections at screening or randomisation; Subjects should not have subacute or acute fevers of >101 degrees F at time of screening or randomisation Evidence of prolonged QT interval at screening or randomization (defined as QTc of >450 ms) .or known congenital long-QT syndrome. Neutropenia defined as an absolute neutrophil count of <1,500/µl, Thrombocytopenia defined as platelet count <100 × 103/µl, Current blood clotting or bleeding disorder, or significantly abnormal INR-prothrombin time or partial thromboplastin time at screening, or clinically significant abnormalities in other screening laboratories, including significant abnormalities in vitamin B12 or thyroid function tests would be cause for exclusion.- Abnormal liver function test results defined as aspartate aminotransferase (AST) >2.0 x upper limit of normal (ULN); alanine aminotransferase (ALT) >2.0 x ULN; and / or total bilirubin >1.5 x ULN; Known allergy or intolerance to AZD0530 or any excipients used in the investigational medicinal products. Simultaneous participation in another interventional clinical study or a non-interventional study with imaging measures or invasive procedures (eg. collection of blood or tissue samples); Participation in the FOP Connection Registry (www.fopconnection.org) or other studies in which patients completed study questionnaires are possible. Treatment with another investigational or drug that might interfere with HO formation and the interpretation of the study drug in the last 90 days Current use or history of regular alcohol consumption exceeding 14 units/week (6 glasses of 13.0% wine (175ml), 6 pints of 4.0% lager or ale (568ml), 5 pints of 4.5% cider (568 ml) or 14 glasses of 10.0% spirits (25ml)) within 6 months of screening. Currently active metabolic bone disease, other than FOP.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bernard J Smilde, MD
Phone
+31204444444
Email
b.smilde@amsterdamumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Elisabeth MW Eekhoff, MD, PhD
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elisabeth MW Eekhoff, MD, PhD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klinikum Garmish-Partenkirchen
City
Garmisch-Partenkirchen
ZIP/Postal Code
82467
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clemens Stockklausner, MD, PhD
Facility Name
Amsterdam University Medical Center
City
Amsterdam
ZIP/Postal Code
1081HV
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernard J Smilde, MD
Email
b.smilde@amsterdamumc.nl
Facility Name
Royal National Orthopaedic Hospital
City
London
ZIP/Postal Code
HA7 4LP
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Richard Keen, MD, PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
35650602
Citation
Smilde BJ, Stockklausner C, Keen R, Whittaker A, Bullock AN, von Delft A, van Schoor NM, Yu PB, Eekhoff EMW. Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP). BMC Musculoskelet Disord. 2022 Jun 1;23(1):519. doi: 10.1186/s12891-022-05471-x.
Results Reference
derived

Learn more about this trial

Saracatinib Trial TO Prevent FOP

We'll reach out to this number within 24 hrs